New Research Reveals What Ozempic Does to Your Brain: It May Reduce the Risk of Dementia 48 percent
GLP-1 drugs show promise in curbing the risk of cognitive problems
Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 diabetes and shedding pounds. But have you ever wondered what Ozempic does to your brain? Recent research suggests it might do far more than regulate blood sugar. It could also play a role in reducing the risk of dementia.We asked the experts to weigh in on the latest research and clinical trials.
GLP-1 drugs do more than manage glucose and aid weight loss
Medications known as GLP-1 agonists are FDA-approved for diabetes management and some for weight loss. GLP-1 agonists mimic a natural hormone to regulate insulin production, digestion and appetite.
But the drug used to manage diabetes is now potentially offering unexpected benefits. Semaglutide — the active ingredient in Ozempic and Wegovy — shows promise in reducing the risk of cardiovascular and kidney diseases, fatty liver disease and even obesity-related cancers.
What Ozempic does to your brain
Any brain-related benefits remain speculative at this stage, explains Gregory Barone, DO, an endocrinologist with New Jersey-based Cooper University Health Care. “The outcome-based data is really promising for this drug class,” Dr. Barone says. “But a lot is still up for the scientists of the world to sort out.”
Emerging studies suggest the diabetes drug might protect against the risk of cognitive decline, including dementia, Parkinson’s and Alzheimer’s. It could also curb addictive behaviors, such as problems with nicotine dependence. However, the exact mechanisms behind these effects are still unclear.
“The question is, ‘why?’” Dr. Barone says. “Is it something inherent about the semaglutide molecule itself, or are these benefits due to secondary effects like weight loss, decreased inflammation, or changes in consumption habits?”
Ozempic may reduce the risk of dementia 48 percent
The idea that diabetes medication could protect against cognitive decline might seem surprising, but the evidence is growing. A recent University of Oxford study, published in Lancet eClinicalMedicine, suggests that GLP-1 agonists like Ozempic may lower the risk of developing dementia in patients with diabetes by 48 percent compared to those taking sitagliptin (Januvia).
Patients prescribed semaglutide had a reduced risk of developing 22 brain and psychiatric disorders within one year of treatment compared to those on other diabetes drugs. Since diabetes is a known risk factor for cognitive decline, this makes GLP-1 medications like Ozempic especially promising, says Dr. Barone.
However, important questions remain, including how GLP-1 agonists like Ozempic protect the brain and to what extent. The Oxford study was observational, meaning it shows associations but doesn’t prove cause and effect, Dr. Barone notes.
“Dementia can develop through various pathways, one of the more common being vascular dementia, which is related to blood vessel health,” Dr. Barone says. “Since these medications improve cardiovascular outcomes — like reducing the risk of heart disease and stroke — it’s not a big leap to think they might also help maintain vascular health in the brain, potentially reducing the risk of vascular dementia.”
“But dementia progresses at different rates in different people, so it’s challenging to say if a patient’s trajectory has changed,” he adds.
More ways Ozempic affects your brain
While the focus of recent studies has been on the risk of cognitive problems, researchers are also exploring Ozempic’s potential in treating other brain-related conditions, including addictions like gambling and alcohol dependence.
The University of Oxford study also found that Ozempic significantly reduced nicotine dependence in patients, suggesting it may play a role in reducing addictive behaviors.
GLP-1 drugs like Ozempic act on cravings in the brain
GLP-1 agonists reduce constant thoughts about hunger. This allows patients to think more clearly and stay focused, says Dr. Barone. The reduction in food preoccupation could extend to other cravings as well.
“People who struggle with obesity often have abnormal brain signaling, where food is perceived as an addiction — similar to how smokers or alcoholics crave or depend on their fixes,” says Dr. Barone.
“We know semaglutide works primarily at the appetite center, but it’s suspected that the nearby reward center could also be involved,” he notes. “There may be some cross-signaling that blunts cravings not just for food, but for other addictive behaviors.”
What Ozempic does to your brain: The bottom line
While the science behind these additional Ozempic benefits is plausible, Dr. Barone says it’s far too early to say if and how GLP-1 drugs can be repurposed to protect the brain.
“The outcome-based data we have is incredibly promising, particularly for diabetes, heart disease and kidney health,” Dr. Barone adds. “As for cognitive benefits, we’re still waiting for more concrete evidence.”
Conversation
All comments are subject to our Community Guidelines. First For Women does not endorse the opinions and views shared by our readers in our comment sections. Our comments section is a place where readers can engage in healthy, productive, lively, and respectful discussions. Offensive language, hate speech, personal attacks, and/or defamatory statements are not permitted. Advertising or spam is also prohibited.
